NextCure Inc. (NXTC)’s Financial Results Comparing With Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Since NextCure Inc. (NASDAQ:NXTC) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation of both companies.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NextCure Inc. 22 305.03 N/A -2.18 0.00
Regeneron Pharmaceuticals Inc. 335 4.27 N/A 20.54 14.84

Table 1 shows the top-line revenue, earnings per share and valuation for NextCure Inc. and Regeneron Pharmaceuticals Inc.

Profitability

Table 2 provides us NextCure Inc. and Regeneron Pharmaceuticals Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
NextCure Inc. 0.00% 0% 0%
Regeneron Pharmaceuticals Inc. 0.00% 29.2% 21.4%

Liquidity

NextCure Inc.’s Current Ratio and Quick Ratio are 12.8 and 12.8 respectively. The Current Ratio and Quick Ratio of its competitor Regeneron Pharmaceuticals Inc. are 4.6 and 4 respectively. NextCure Inc. therefore has a better chance of paying off short and long-term obligations compared to Regeneron Pharmaceuticals Inc.

Analyst Ratings

NextCure Inc. and Regeneron Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
NextCure Inc. 0 0 3 3.00
Regeneron Pharmaceuticals Inc. 0 2 1 2.33

NextCure Inc. has a 17.87% upside potential and an average target price of $43.67. Regeneron Pharmaceuticals Inc. on the other hand boasts of a $425.25 average target price and a 51.00% potential upside. The information presented earlier suggests that Regeneron Pharmaceuticals Inc. looks more robust than NextCure Inc. as far as analyst view.

Insider & Institutional Ownership

Roughly 30.8% of NextCure Inc. shares are owned by institutional investors while 73.9% of Regeneron Pharmaceuticals Inc. are owned by institutional investors. 3.5% are NextCure Inc.’s share owned by insiders. Competitively, insiders own roughly 20% of Regeneron Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NextCure Inc. 14.31% 24.48% 0% 0% 0% 10.4%
Regeneron Pharmaceuticals Inc. -2.83% -3.73% -10.57% -27.42% -17.97% -18.4%

For the past year NextCure Inc. has 10.4% stronger performance while Regeneron Pharmaceuticals Inc. has -18.4% weaker performance.

Summary

Regeneron Pharmaceuticals Inc. beats NextCure Inc. on 6 of the 10 factors.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.